PD-1/L1

Delve into the world of PD-1/L1 in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on PD-1/L1 to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination
CompanyDrug

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination

Eli Lilly and Company (NYSE: LLY) announced new first‑line data on olomorasib, its investigational next‑generation KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid,…

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

SCIEX Breaks Ground on Beijing Mass Spectrometry Manufacturing Site – Danaher's 10th Production Facility in China, Making Beijing Its First City Globally with Three Manufacturing Sites

SCIEX Breaks Ground on Beijing Mass Spectrometry Manufacturing Site – Danaher’s 10th Production Facility in China, Making Beijing Its First City Globally with Three Manufacturing Sites

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

BMS Reports Positive Phase III Results for Opdivo and Yervoy in Advanced HCC

CompanyDrug

AstraZeneca’s Lynparza-Imfinzi Combo Shows Promising Results in Endometrial Cancer Study

CompanyDrug

GSK’s Jemperli Shows Survival Benefits in Phase III Endometrial Cancer Study

CompanyDrug

BeiGene’s Tislelizumab Receives FDA Approval for Esophageal Squamous Cell Carcinoma

CompanyDrug

Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma

CompanyDeals

MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer

CompanyDrug

Bio-Thera Solutions Gets Green Light for Phase Ib/II Study of ADC BAT8008 in Advanced Solid Tumors

CompanyDrug

Innovent and HutchMed’s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer

Show More